V accines based on inactivated or attenuated influenza viruses are an effective strategy to prevent influenza disease, but they rely on an appropriate choice of strains to be used for the vaccine before the season commences (1, 2) . The annual selection of vaccine strains in the Northern and Southern hemispheres is necessitated by the continuous antigenic evolution of influenza viruses, which contributes to seasonal differences in the distribution of subtypes and strains as well as the appearance of new subtypes and strains (3) (4) (5) (6) (7) (8) . Vaccine failure may arise from the emergence of mismatched strains antigenically drifted or unrelated to the vaccine strains (7, 9, 10) . Hence, an estimation of the level of vaccine effectiveness may be derived from the determination of the antigenicities of clinical breakthrough strains relative to the relevant vaccine strain.
Genetic changes underlie the emergence of new influenza virus strains (11, 12) . Antigenic drift and shift are associated with modifications that include point mutations in the former and reassortment of genetic material between the genomes of viruses coinfecting the same host in the latter (13) (14) (15) . The evolution of the H3N2 influenza virus strain, since its appearance in humans in 1968, is demonstrative of how drift is also associated with dominant lineage replacement over time (13, 16) . Mutations associated with antigenic drift have been identified in the hemagglutinin (HA) gene, including around the sialic acid binding site, as well as other prominent antigenic sites (13, (16) (17) (18) (19) (20) (21) (22) (23) (24) . The appearance of a new drifted strain is generally associated with several mutations, but drift associated with a single amino acid residue mutation (N145K) may also occur (13) .
Although there is a correlation between the antigenic and genetic evolution of influenza virus strains, the predictive power is not necessarily high enough to determine which mutations (even those near the sialic acid binding site) will translate into an antigenically drifted strain (13, 20) . Indeed, the same single amino acid substitution in an identical position of the HA1 domain can have opposing effects on phenotype in two different strains of the same lineage (25) . However, genetic-based prediction models of antigenic drift are attractive because they are based on the genetic detection of viruses, and this method is analytically sensitive and relatively easy to perform (7, 15, 26 ). Yet, genetic-based prediction of antigenicity has not been examined in the context of a prospective vaccine efficacy clinical trial. In these trials, breakthrough cases are relatively infrequent, and the determination of antigenicity has been reliant on the conventional hemagglutination inhibition (HI) assay (27) , which is limited by the availability of relevant reference strain ferret antisera (28) and the potential difficulties of cultivating sufficient virus from clinical samples. PCR has already been shown to be a more sensitive technique than culture at detecting influenza virus in nasal/throat swab samples from clinical breakthrough cases after vaccination (29) . The aim of this study was to explore the relationship between HA1 domain sequences and antigenicities (determined by HI) of influenza virus strains isolated from clinical breakthrough cases. These cases occurred during the follow up of a large international and multicenter clinical trial evaluating the relative efficacy of two trivalent influenza virus vaccines that was conducted over the 2008-2009 season in Ͼ43,000 adults Ն65 years old (30) .
(This study has been registered at ClinicalTrials.gov under registration no. NCT00753272.)
MATERIALS AND METHODS
Clinical trial conduct. The observer-blinded randomized trial (ClinicalTrials.gov registration no. NCT00753272 [http://clinicaltrials.gov/show /NCT00753272]) was conducted at multiple sites in 15 countries in the Northern Hemisphere involving subjects who were Ն65 years old at trial entry (30) . The trial was approved by the research ethics committees of all participating countries and conducted in accordance with the Declaration of Helsinki and good clinical practice guidelines. Written informed consent was obtained from all subjects before trial entry. Approximately half of the subjects received GlaxoSmithKline (GSK) Vaccine's Fluarix (Fluarix is a trade mark of the GlaxoSmithKline group of companies), and the remainder received GSK's candidate formulation of split antigens adjuvanted with AS03 B (GSK Vaccine's proprietary adjuvant system containing 5.93 mg ␣-tocopherol and squalene in an oil-in-water emulsion). Both Sampling. Nasal and throat swabs for culture and PCR were taken up to 5 days after the onset of an influenza-like episode (Fig. 1A) and stored in M4RT transport medium (Remel, United Kingdom) at Ϫ70°C. An influenza-like illness was defined as the simultaneous occurrence of at least one respiratory symptom (nasal congestion, sore throat, new or worsening cough, new or worsening dyspnea, new or worsening sputum production, and new or worsening wheezing) and one systemic symptom (headache, fatigue, myalgia, feverishness, and fever [oral temperature of Ն37.5°C]).
Influenza virus culture-based typing. Nose/throat swab samples were stored at Ϫ70°C. After thawing, these were cultured both on rhesus monkey kidney (RMK) cells and Madin-Darby canine kidney (MDCK) cells with incubation at 33 to 36°C for up to 2 weeks. Influenza virus A/B typing was performed on fixed cell cultures using standard immunofluorescence histology with influenza virus A-/B-specific antibodies (29) .
Influenza virus antigenic typing and HI assay. The HI assay was performed using a standard protocol (31) . Validated vaccine strain monospecific antisera were prepared from infected ferrets using a bank of influenza virus vaccine strains (at GlaxoSmithKline Vaccines) and were treated with HA receptor-destroying enzyme (32) . The influenza virus antigen controls were produced and validated by the Centers for Disease Control and Prevention. Each HI assay was performed in triplicate using an appropriate vaccine strain virus control or an influenza virus specimen prepared from infected cell cultures (8 HA units/25 l), serial dilutions of the appropriate ferret-derived vaccine strain antiserum, and 0.5% turkey erythrocytes. The HI titer was defined as the highest dilution step for complete inhibition of hemagglutination. The definition of relative HI titer and the designation of a specimen as vaccine strain matched, drifted, or mismatched are described in Table 1 .
Influenza virus detection and PCR typing. Influenza virus detection and A/B typing were performed using quantitative real-time PCR (qPCR) targeting the matrix gene on RNA prepared from total nucleic acid extracted from frozen samples of nose/throat swabs, as described previously (29) . Subtyping of influenza virus A-positive cases into seasonal A(H1N1) and A(H3N2) was performed in a separate reverse transcription-PCR (RT-PCR) assay using different sets of primers targeting the hemaggluti- Sequencing and sequence analysis. The PCR product corresponding to the HA1 domain of the HA gene was sequenced with an automated ABI 3130xl genetic analyzer using a standard DNA sequencing protocol and specific primers. Phylogenetic clustering was performed using the MEGA 4 software with comparisons to vaccine strain homologous or heterologous reference strain sequences as used by the WHO Collaborating Centre for Reference and Research on Influenza, London, United Kingdom (33) (34) (35) . A virus specimen was classified as homologous to a given vaccine strain when the HA1 nucleic acid sequence of the virus specimen aligned within the same clade as the vaccine strain or vaccine strain homologous reference strain and included the amino acid residue substitution(s) that had also been used to define the clade (33) (34) (35) . A vaccine specimen was classified as heterologous when its HA1 nucleic acid sequence aligned within the same clade as a vaccine strain heterologous reference strain and included the amino acid residue substitution(s) that had also been used to define the clade (33-35) (see Table 1 for definitions). HA1 sequence group allocation was determined by the amino acid residue substitutions relative to the vaccine strain (or a strain that defined the lineage, in the case of B[Victoria]), using characterized amino acid residue positions in the antigenic sites of the HA1 domain as references (see Table S1 in the supplemental material).
RESULTS
Influenza virus was detected in 603 specimens by qPCR or by cell culture and classified as seasonal influenza A (509 specimens) or influenza B (94 specimens) virus. Further subtyping by PCR classified 380 specimens as A(H3N2), 29 as A(H1N1), 23 as B(Yamagata), and 66 as B(Victoria) (Fig. 1) . The pandemic influenza virus A(H1N1)pdm09 was detected in only five specimens by specific qPCR (30) and was not considered for this analysis (not shown). Culturing of the virus was unsuccessful in 50% (191/380) of the A(H3N2) specimens, whereas it was unsuccessful in only 9 to 14% of the specimens from the other subtypes (Fig. 1B) . All of the virus specimens that were successfully cultured were also cultured in RMK cells, whereas not all of these specimens were successfully cultured in MDCK cells. Hence, the HI testing was performed with RMK-cultured viruses only. HI titers relative to the relevant vaccine strains and PCR subtyping were determined in 48% (182/380), 86% (25/29), 87% (20/23), and 89% (59/66) of the A(H3N2), A(H1N1), B(Yamagata), and B(Victoria) specimens, respectively.
The subtyped influenza virus specimens for which HA1 sequences were determined were allocated to HA1 domain sequence groups (HA1 groups) based on particular combinations of amino acid substitutions at five antigenic sites (Tables 2, 3 , and 4). The 379 A(H3N2) specimens were allocated to 25 groups (Table 2) , most of which (259 specimens) were in group 1. The A(H1N1) specimens were allocated to eight groups ( Table 3 ). The 23 B(Yamagata) specimens were allocated to three groups, and the 66 B(Victoria) specimens were allocated to seven groups (Table 4 ).
An influenza virus was classified as homologous or heterologous to a vaccine strain by phylogenetic clustering based on the HA1 domain nucleic acid sequence, with the vaccine strain and other characterized influenza virus strains as references (Fig. 2 , Table 1 ). A total of 377 A(H3N2) viruses in 24/25 HA1 groups were classified as homologous to the A/Brisbane/10/07 vaccine strain ( Fig. 2A) . The two A(H3N2) viruses in the remaining group (group 6) were classified as heterologous to the vaccine strain and homologous to the A/Perth/16/09 strain. All 29 A(H1N1) viruses were homologous to the vaccine A/Brisbane/59/07 strain (Fig.  2B ). Only two B(Yamagata) viruses from one HA1 group (group 0) were homologous to the B/Florida/04/06 vaccine strain (Fig.  2C) . Twenty viruses in the Yamagata lineage were classified as heterologous to the vaccine strain and homologous to the B/Bangladesh/3333/07 strain. Sixty-six viruses in the Victoria lineage were heterologous to the vaccine strain (Fig. 2D) . In addition to the RNA mutations associated with the amino acid substitutions that defined the HA1 sequence groups, other mutations were identified, and these contributed to differences in the positioning of individual viruses in the phylogenetic trees.
The A(H3N2) viruses classified as homologous by sequencing included as many as six additional amino acid substitutions in the antigenic sites relative to the vaccine strain (i.e., in HA1 groups 16 and 22) , and viruses in the largest HA1 group, group 1, included three additional substitutions ( Table 2 ). The A(H1N1) viruses classified as homologous included as many as four additional amino acid substitutions, and the B(Yamagata) viruses classified as homologous included one additional amino acid substitution (Tables 3 and 4) . Nevertheless, the N144K substitution distinguished the two heterologous A(H3N2) viruses from the homologous A(H3N2) viruses, and the S150I/V and N165Y substitutions distinguished the heterologous B/Yamagata viruses from the homologous B/Yamagata viruses (Tables 2 and 4) .
Most viruses for which HA1 sequences and relative HI titers were determined belonged to the A(H3N2) lineage (Fig. 1B and Table 5 ). Relative HI titers were determined for 180 A(H3N2) viruses classified as homologous by sequence, and these titers encompassed a broad range from 2 to Ϫ64, with median and mode relative titers of Ϫ2 and 0, respectively (Table 5, Fig. 3 ). In the largest HA1 group, group 1, the 123 relative HI titers also ranged from 2 to Ϫ64. Among all the homologous A(H3N2) viruses, 16% (29/180) were classified as drifted (Table 5 , Fig. 3) . No HA1 group Relative HI titer A relative HI titer was derived from the ratio of the HI titer for the vaccine-strain antiserum against the virus-specimen (virus specimen HI titer) over the HI titer for the vaccine-strain antiserum against the vaccine-strain antigen (the reference HI titer). A ratio of Յ0.5 was given the value equal to the negative reciprocal of the ratio; a ratio of 1 was given the value of zero, and a ratio of Ն2 kept the same value. Vaccine-strain matched
Virus with an HI titer that was no more than 4-fold lower than the reference HI titer (i.e., the relative HI titer was ՆϪ4).
Vaccine-strain mismatched
Virus with an HI titer that was more than 4-fold lower than the reference HI titer (i.e., the relative HI titer was ϽϪ4).
Vaccine-strain drifted
Virus that was mismatched and in the same lineage as the vaccine strain Vaccine-strain homologous
Virus with an HA1 nucleic acid sequence that aligned with the same clade as the vaccine or vaccine-strain homologous reference strain Vaccine-strain heterologous
Virus with an HA1 nucleic acid that aligned with a clade defined as heterologous to the clade of the vaccine strain contained more than one drifted virus apart from HA1 group 1, in which 15% (22/123) were drifted. For the A(H3N2) viruses classified as heterologous by sequence, the two relative HI titers were Ϫ4 and Ϫ8. HA1 sequences and relative HI titers were determined for 25 A(H1N1) viruses, and 16% (4/25) of these A(H1N1) viruses were classified as drifted (Fig. 3) . The relative HI titers for all viruses tested encompassed a broad range from 2 to Ϫ16, with median and mode relative titers of Ϫ4 (Fig. 3) . In the three HA1 groups with more than three viruses, the relative titers ranged from 0 to Ϫ4, Ϫ2 to Ϫ8, and Ϫ2 to Ϫ16.
Two viruses classified as homologous by sequence in the B(Yamagata) lineage gave relative HI titers ofϪ4 for both (Fig. 3) .
Eighteen B(Yamagata) viruses classified as heterologous by sequence gave relative HI titers that ranged from Ϫ4 to Ϫ32, with median and mode titers of Ϫ16. Seventy-two percent (13/18) of these viruses were also classified as drifted. Fifty-nine viruses in the B(Victoria) lineage classified as heterologous by sequence gave relative HI titers that were either Ϫ16 or Ϫ32, with median and (5) N133N/S, S138A P194L K173Q Y94H G13 (5) N122D/I, S138A P194L K173Q G14 (6) S138A, R142K P194L Q44Q/H K173Q G15 (7) S138A, N144S P194L K173Q G16 (7) S138A L157S, P194L, A198A/T K173Q L59L/I G17 (6) S138A K158R, P194L K173Q G18 (6) S138A I192T, P194L K173Q G19 (4) S138A P194L K173Q, V204I G20 (6) S138A mode titers of Ϫ32 (Fig. 3 ). All these 59 viruses were classified as mismatched.
For each of the influenza viruses classified as homologous by sequence and classified as antigenically drifted, the HA1 domain sequence was determined in the RMK-cultured isolate and compared with the respective sequence determined from the nasal/ throat swabs (see Table S2 in the supplemental material). For the 29 A(H3N2) viruses examined after culturing, three (10%) contained revertant (i.e., A138S) or additional amino acid residue substitutions in antigenic sites, and seven (24%) contained amino acid residue substitutions in or next to antigenic sites. For the four influenza A(H1N1) viruses examined after culturing, two (50%) contained additional amino acid residue substitutions in antigenic sites. None of the substitutions affected the designation of a virus as vaccine strain homologous.
DISCUSSION
Influenza virus vaccine effectiveness can differ from one season to the next because of the appearance of strains that are antigenically drifted or mismatched to the vaccine strain (28, 36, 37) . Determining whether influenza viruses isolated from clinical breakthrough cases are drifted or mismatched to the vaccine strains is therefore necessary to appropriately estimate vaccine effectiveness (7, 9, 10), but it is challenging because of the requirement to use culture-based methods (26) . Moreover, in the context of a vaccine efficacy clinical trial, the number of breakthrough cases detected through culture-based methods may be relatively small, especially if the attack rate is unusually low in a given season (38) . The use of PCR is highly attractive because of its sensitivity and ease of application (7, 36, 37, 39) . In this study, and in agreement with a recent report, PCR represented a sensitive and accurate method for iden- tifying and typing influenza virus strains in samples from randomized prospective clinical trials (29) . PCR also appeared to be more efficient at detecting A(H3N2) viruses than the culturebased methods, possibly related to the reduced sensitivity of culture method with A/Brisbane/10/07 lineage strains (29, 39, 40) .
In the current study, the majority of detected strains were from the A(H3N2) lineage (most of which were antigenically matched with the vaccine strain), with a minority of strains being from the seasonal A(H1N1) and B lineages. The relative frequencies of the influenza virus strain subtypes were consistent with the circulating strains observed by the influenza surveillance networks in the countries where subjects were enrolled (e.g., 41, 42) . Therefore, certain factors that are common to vaccinated individuals in this study and to those in the general population, such as those related to environmental or genetic predisposition, may have contributed to the occurrence of breakthrough cases. Moreover, breakthrough cases associated with vaccine-matched influenza virus strains were to be expected because seasonal influenza virus vaccines have been found to be only partially effective even against circulating vaccine-matched strains (43) . Using the HA1 nucleic acid sequence to classify influenza viruses as vaccine strain homologous or vaccine strain heterologous was consistent with antigenicity for the majority of viruses examined. Eighty-four percent of the A(H3N2) and A(H1N1) viruses classified as homologous by sequence were matched to the respective vaccine strains, and conversely, 72% of the B(Yamagata) influenza viruses classified as heterologous by sequence drifted from the vaccine strain. Nevertheless, the wide range of titers among the larger HA1 groups suggests that the HA1 domain sequence was not necessarily a reliable predictor of antigenicity or that a particular HA1 substitution was associated with a drift. These wide ranges of titers were most notable in the two largest HA1 groups of A(H3N2) and A(H1N1) viruses classified as homologous by sequence, and corresponded to 128-and 16-fold difference in relative HI titers, respectively. Moreover, the homologous A(H3N2) and A(H1N1) viruses that were classified as antigenically drifted appeared not to be highly associated with particular HA1 groups. And although the HA1 sequence may have harbored other amino acid substitutions not used in the HA1 group classification (data not shown), there was no evidence that these substitutions were associated with drift either.
Other factors may have affected the relative HI titers of the drifted viruses, such as mutations that can potentially reduce virus 
FIG 3
The number of virus specimens according to relative HI titers for homologous and heterologous A(H3N2) types, homologous A(H1N1) types, homologous and heterologous B(Yamagata) types, and heterologous B(Victoria) types. Each bar for a relative HI titer includes the respective number of specimens from each HA1 domain group (separated by horizontal lines in the bar, ranked by the overall total number of specimens in the HA1 group and differently shaded and patterned for the highest eight ranked HA1 groups, with HA1 groups ranked Ն9 in dark gray). Note that no heterologous A(H1N1) specimens were identified, and only single groups of two specimens were identified for heterologous A(H3N2) specimens and homologous B(Yamagata) specimens.
avidity to turkey erythrocytes (44, 45) or mutations that can affect neuraminidase function (45, 46) , thus confounding the use of the HA1 sequence alone for classifying vaccine strain relatedness. The cell culture-related amino acid residue substitutions in the HA1 domain also might have affected the HI titers; and although these substitutions were not evaluated further, they were only identified in a minority of the viruses that were classified as homologous by sequence and classified as antigenically drifted. Moreover, such artifacts associated with the cell culturing of virus reflect a potential limitation of the HI assay for antigenic typing (47) (48) (49) . Indeed, the time taken for the emergence of a new immunodominant drifted strain was 3.3 years on average in the cluster analysis of H3N2 strain evolution using the HA1 domain sequence (13) . Moreover, the center of a new drifted strain cluster was separated from the center of the parental strain cluster by an average of 4.45 antigenic distance units, corresponding to a 22-fold (2 4.45 ) difference in relative HI titers, and by an average of 13 amino residue substitutions (13) . In the current study, although a wide variation in relative HI titers (and hence in antigenic distances) for a given HA1 group was identified, the genetic variation observed might be accommodated within a single-strain cluster. Hence, in a single season, the HA1 sequence appears to be unsuitable for an estimation of vaccine efficacy or for the identification of potentially new immunodominant strains, because the prediction of antigenicity and class-matched and -mismatched viruses from individual clinical breakthrough cases was not reliable. Therefore, the HI assay should remain the preferred method for determining the relatedness between circulating strains and vaccine strains. However, epidemiological monitoring of genetic evolution performed over numerous seasons, rather than a single season, may provide a basis for more accurate predictions.
